HealthMore in Health→
Biotech Briefing: Vivatides Raises $54 Million as Wegovy Distribution and Gilead Dealmaking Move Forward
A new China-U.S. biotech raised $54 million for preclinical RNA therapies, while Wegovy distribution rules changed in Europe and Gilead exercised a $45 million Kymera option.
Key Takeaways
- Vivatides Therapeutics raised a $54 million Series A for preclinical RNA-focused R&D.
- Endpoints reports Wegovy is dropping cold-chain requirements in the EU.
DE
DT Editorial Team··via endpoints.news